Laboratory of Pharmaceutical Analysis and Drug Metabolism, College of Pharmaceutical Sciences, Zhejiang University , Zhejiang 310058, China.
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan , Ann Arbor, Michigan 48109, United States.
Mol Pharm. 2018 Feb 5;15(2):385-393. doi: 10.1021/acs.molpharmaceut.7b00728. Epub 2018 Jan 2.
The proton-coupled oligopeptide transporter PHT1 (SLC15A4), which facilitates cross-membrane transport of histidine and small peptides from inside the endosomes or lysosomes to cytosol, plays an important role in intracellular peptides homeostasis and innate immune responses. However, it remains a challenge to elucidate functional properties of the PHT1 transporter because of its subcellular localization. The purpose of this study was to resort hPHT1 protein from the subcellular to outer cell membrane of MDCK cells stably transfected with human PHT1 mutants, and to characterize its functional activity in these cells. Using this model, the functional activity of hPHT1 was evaluated by cellular uptake studies with d-l-histidine, GlySar, and the bacterial peptidoglycan products MDP and Tri-DAP. We found that the disruption of two dileucine motifs was indispensable for hPHT1 transporter being preferentially targeting to plasma membranes. hPHT1 showed high affinity for d-l-histidine and low affinity for GlySar, with K values of 16.3 ± 1.9 μM and 1.60 ± 0.30 mM, respectively. Moreover, the bacterial peptidoglycan components MDP and Tri-DAP were shown conclusively to be hPHT1 substrates. The uptake of MDP by hPHT1 was inhibited by di/tripeptides and peptide-like drugs, but not by glycine and acyclovir. The functional activity of hPHT1 was also pH-dependent, with an optimal cellular uptake in buffer pH 6.5. Taken together, we established a novel cell model to evaluate the function of hPHT1 in vitro, and confirmed that MDP and Tri-DAP were substrates of hPHT1. Our findings suggest that PHT1 may serve as a potential target for reducing the immune responses and for drug treatment of inflammatory diseases.
质子偶联寡肽转运蛋白 PHT1(SLC15A4)促进组氨酸和小肽从内体或溶酶体跨膜转运到细胞质,在细胞内肽稳态和先天免疫反应中发挥重要作用。然而,由于其亚细胞定位,阐明 PHT1 转运蛋白的功能特性仍然是一个挑战。本研究的目的是从稳定转染人 PHT1 突变体的 MDCK 细胞的亚细胞内体到质膜上将 hPHT1 蛋白募集,并在这些细胞中表征其功能活性。使用该模型,通过用 d-l-组氨酸、GlySar 和细菌肽聚糖产物 MDP 和 Tri-DAP 进行细胞摄取研究来评估 hPHT1 的功能活性。我们发现,两个二亮氨酸基序的破坏对于 hPHT1 转运蛋白优先靶向质膜是必不可少的。hPHT1 对 d-l-组氨酸表现出高亲和力,对 GlySar 表现出低亲和力,K 值分别为 16.3 ± 1.9 μM 和 1.60 ± 0.30 mM。此外,细菌肽聚糖成分 MDP 和 Tri-DAP 被明确证明是 hPHT1 的底物。MDP 被 hPHT1 的摄取被二肽/三肽和肽样药物抑制,但不受甘氨酸和阿昔洛韦的抑制。hPHT1 的功能活性也依赖于 pH,在缓冲液 pH 6.5 时细胞摄取最佳。总之,我们建立了一种新的细胞模型来评估 hPHT1 的体外功能,并证实 MDP 和 Tri-DAP 是 hPHT1 的底物。我们的研究结果表明,PHT1 可能成为减少免疫反应和治疗炎症性疾病的潜在药物靶点。